alpha-aminopyridine has been researched along with everolimus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (82.61) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Chen, M; Khuri, FR; Owonikoko, TK; Ramalingam, SS; Ren, H; Sun, SY; Tao, H; Yue, P | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Boukouris, AE; Buitrago-Molina, LE; Hegermann, J; Kirstein, MM; Kühnel, F; Manns, MP; Marhenke, S; Orlik, J; Pothiraju, D; Schütt, J; Vogel, A | 1 |
| Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L | 1 |
| Badura, S; Falkenburg, JH; Liebermann, M; Nijmeijer, BA; Ottmann, OG; Pfeifer, H; Ruthardt, M; Tesanovic, T; Wystub, S | 1 |
| Aymerich, M; Beà, S; Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Salaverria, I; Xargay-Torrent, S | 1 |
| Adetchessi, T; Barlier, A; Chinot, O; Defilles, C; Dufour, H; Enjalbert, A; Figarella-Branger, D; Fuentes, S; Germanetti, AL; Graillon, T; Lisbonis, C; Metellus, P; Mohamed, A; Roche, PH | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Koh, J; Ku, BM; Lee, SH; Park, K; Sun, JM; Yi, SY | 1 |
| de Gruijl, TD; de Haas, RR; Huijts, CM; Quiles Del Rey, M; Santegoets, SJ; van der Vliet, HJ; Verheul, HM | 1 |
| Alexander, BM; Claus, EB; Du, R; Goel, S; Guo, H; Hayashi, M; Iglehart, JD; Kang, YJ; Krop, IE; Ligon, AH; Ligon, KL; Lin, NU; Luu, V; Marco, E; Nguyen, QD; Ni, J; Ramkissoon, LA; Ramkissoon, SH; Roberts, TM; Stover, DG; Wang, ZC; Winer, EP; Xie, S; Yuan, GC; Zhao, JJ | 1 |
| Chaire, V; Fourneaux, B; Italiano, A; Karanian, M; Laroche-Clary, A; Lucchesi, C; Pineau, R | 1 |
| Aristizabal Prada, ET; Auernhammer, CJ; Maurer, J; Nölting, S; Spoettl, G | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| Auriemma, RS; Cappabianca, P; Cavallo, LM; Colao, A; De Martino, MC; Di Cera, M; Frio, F; Grasso, LFS; Patalano, R; Pivonello, C; Pivonello, R; Solari, D; Vitulli, F | 1 |
| Bøttcher, TM; Cold, S; Jensen, AB | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Akce, M; Alese, OB; Bilen, MA; Carthon, B; Chen, Z; Collins, H; El-Rayes, BF; Harris, WB; Harvey, RD; Khuri, FR; Kudchagkar, RR; Lawson, DH; Lewis, C; Lonial, S; Owonikoko, TK; Ramalingam, SS; Shaib, WL; Sica, GL; Steuer, CE; Wu, C; Zhang, C | 1 |
| Baxter, PA; Bukowinski, A; Campagne, O; DeWire, MD; Dorris, K; Dunkel, IJ; Fouladi, M; Fuller, C; Hoffman, L; Hwang, EI; Karajannis, MA; Lin, T; Onar-Thomas, A; Pan, H; Stewart, CF; Waanders, AJ; Young Poussaint, T | 1 |
| Bou-Ayache, J; Chaft, J; Chan, J; Chou, J; Hauser, H; Perez, K; Rafailov, J; Raj, N; Reidy-Lagunes, D; Rudin, C; Sawan, P; Tang, L; Zheng, Y | 1 |
| Aboukameel, A; Al-Hallak, MN; Azmi, AS; Baloglu, E; Beydoun, R; Dyson, G; El-Rayes, BF; Kim, SH; Landesman, Y; Li, Y; Mohammad, RM; Mpilla, GB; Philip, PA; Senapedis, WT; Uddin, MH; Viola, NT; Wagner, KU | 1 |
4 review(s) available for alpha-aminopyridine and everolimus
| Article | Year |
|---|---|
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Drugs, Investigational; Everolimus; Female; Humans; Molecular Targeted Therapy; Piperazines; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2019 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
2 trial(s) available for alpha-aminopyridine and everolimus
| Article | Year |
|---|---|
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Prognosis; Survival Rate; Tissue Distribution | 2020 |
A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.
Topics: Adolescent; Adult; Age Factors; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Purines; Treatment Outcome; Young Adult | 2021 |
17 other study(ies) available for alpha-aminopyridine and everolimus
| Article | Year |
|---|---|
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Culture Media, Serum-Free; Drug Synergism; Everolimus; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Recombinant Fusion Proteins; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2012 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Topics: Aminopyridines; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Respiration; Cisplatin; Doxorubicin; Everolimus; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Everolimus; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Topics: Aminopyridines; Antineoplastic Agents; Drug Synergism; Everolimus; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphocytes; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Naphthyridines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Topics: Aminopyridines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Interleukin-4; Interleukin-6; Lymphoma, Mantle-Cell; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcriptome; Tumor Microenvironment | 2014 |
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cell Cycle; Cell Survival; Drug Therapy, Combination; Everolimus; Female; Humans; Imidazoles; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Morpholines; Neurofibromin 2; Octreotide; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Receptors, Somatostatin; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Everolimus; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
Topics: Aminopyridines; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Cells, Cultured; Cytokines; Everolimus; Flow Cytometry; Humans; Imidazoles; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Sirolimus; T-Lymphocytes, Regulatory; TOR Serine-Threonine Kinases | 2016 |
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Carrier Proteins; Caspase 3; Cell Cycle Proteins; DNA Repair; Drug Resistance, Neoplasm; Drug Therapy, Combination; Eukaryotic Initiation Factors; Everolimus; Female; Gene Expression Profiling; Genomic Instability; Humans; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Receptor, ErbB-2; Remission Induction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Leiomyosarcoma; MAP Kinase Kinase Kinases; Mechanistic Target of Rapamycin Complex 2; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinolines; Rapamycin-Insensitive Companion of mTOR Protein; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Topics: Aminopyridines; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Everolimus; Fluorouracil; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; Purines; Time Factors | 2018 |
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Everolimus; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Rats; Signal Transduction; Thiazoles | 2018 |
Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.
Topics: Aminopyridines; Everolimus; Humans; Middle Aged; Neuroendocrine Tumors; Purines | 2021 |
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cytokines; Drug Therapy, Combination; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred ICR; Mice, SCID; Neuroendocrine Tumors; Nicotinamide Phosphoribosyltransferase; p21-Activated Kinases; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |